Saga comments

Arctic Bioscience’s shares has been admitted to trading on Euronext Growth.

Arctic Bioscience is a Norwegian biotechnology company focused on developing, manufacturing and marketing premium ingredients extracted from herring roe.

The Company raised NOK 300 million through an offering of new shares. In addition, there was an over-allotment (greenshoe option) bringing total proceeds raised in the offering to NOK 345 million. The private placement attracted strong interest from Norwegian and international investors, and was multiple times oversubscribed. The shares in the new issue were sold at NOK 31.00 corresponding to a market capitalisation of NOK 753 million.

Saga Corporate Finance acted as strategic advisor to the Company and board of directors.




Read more


  • Commissioned by: Arctic Bioscience
  • Assigment: IPO
  • Industry: Biotechnology


Arctic Bioscience is a biotech company founded based on specialised know-how and competence on the unique properties of bioactive marine compounds, and has developed a proprietary platform technology that serves two unique businesses developing products for pharmaceutical and nutraceutical application. The Company is strategically located in Ørsta on the West Coast of Norway providing direct access to the raw material, and is led by a team with 30+ years of pharma and marine extracts experience.